两种纳洛酮给药方案患者阿片戒断症状发生率与阿片毒性逆转的比较:回顾性队列研究
该回顾性匹配队列研究在两家城市急诊科进行,正值芬太尼过量流行期间,纳入阿片过量患者,比较初始低剂量纳洛酮(LDN,≤0.15 mg)与高剂量纳洛酮(HDN,>0.15 mg)患者的戒断症状(OW)发生率和阿片毒性逆转率。80例LDN患者与299例HDN患者按初始呼吸频率1:4匹配。调整年龄、性别、纳洛酮前GCS及非阿片药物或酒精存在后,HDN患者初始剂量后出现OW的OR=8.43(95%CI 1.96–36.3,p=0.004),任何剂量后OR=2.56(95%CI 1.17–5.60,p=0.019);HDN患者初始剂量后达逆转标准的OR=2.73(95%CI 1.19–6.26,p=0.018),任何剂量后OR=6.07(95%CI 1.81–20.3,p=0.003)。结论认为HDN患者更易出现OW但也更易达逆转标准。
要点
- 阿片过量患者中,高剂量纳洛酮(>0.15 mg)较低剂量(≤0.15 mg)初始剂量后戒断症状风险更高(OR=8.43,95%CI 1.96–36.3,p=0.004)。
- 高剂量纳洛酮患者任何剂量后戒断症状风险仍高于低剂量组(OR=2.56,95%CI 1.17–5.60,p=0.019)。
- 高剂量纳洛酮患者初始剂量后更易达到阿片毒性逆转标准(OR=2.73,95%CI 1.19–6.26,p=0.018)。
- 高剂量纳洛酮患者任何剂量后达到逆转标准的可能性更高(OR=6.07,95%CI 1.81–20.3,p=0.003)。
- 该研究在芬太尼过量流行期间的两家城市急诊科进行,结果提示需权衡高剂量纳洛酮的逆转获益与戒断风险。
适用人群与场景
- 在两家城市急诊科接受治疗、经历阿片过量的患者,研究期间正值芬太尼过量流行。
- 低剂量纳洛酮组(≤0.15 mg)与高剂量纳洛酮组(>0.15 mg)按初始呼吸频率以1:4比例匹配。
诊断标准与关键阈值
- 戒断症状(OW)与阿片逆转的定义在研究前预先制定(a priori)。
- 低剂量纳洛酮定义为初始剂量≤0.15 mg;高剂量纳洛酮定义为初始剂量>0.15 mg。
处置流程与药物剂量
- 低剂量纳洛酮方案:初始剂量≤0.15 mg。
- 高剂量纳洛酮方案:初始剂量>0.15 mg。
研究设计与关键结果
- 回顾性匹配队列研究,纳入80例低剂量纳洛酮患者与299例高剂量纳洛酮患者,按初始呼吸频率1:4匹配。
- 调整年龄、性别、纳洛酮前GCS及非阿片药物或酒精存在后,高剂量组较低剂量组初始剂量后戒断症状OR=8.43(95%CI 1.96–36.3,p=0.004)。
- 任何剂量后戒断症状:高剂量组较低剂量组OR=2.56(95%CI 1.17–5.60,p=0.019)。
- 初始剂量后达到逆转标准:高剂量组较低剂量组OR=2.73(95%CI 1.19–6.26,p=0.018)。
- 任何剂量后达到逆转标准:高剂量组较低剂量组OR=6.07(95%CI 1.81–20.3,p=0.003)。
证据类型、等级与局限
- 证据类型:回顾性匹配队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于阿片过量患者,高剂量纳洛酮(>0.15 mg)较低剂量(≤0.15 mg)更易达到毒性逆转标准,但也更易出现戒断症状,临床需权衡利弊。
- 该研究在芬太尼过量流行期间的两家城市急诊科进行,结果可能不适用于其他阿片过量场景。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: When managing opioid overdose (OD) patients, the optimal naloxone regimen should rapidly reverse respiratory depression while avoiding opioid withdrawal. Published naloxone administration guidelines have not been empirically validated and most were developed before fentanyl OD was common. In this study, rates of opioid withdrawal symptoms (OW) and reversal of opioid toxicity in patients treated with two naloxone dosing regimens were evaluated.
METHODS: In this retrospective matched cohort study, health records of patients who experienced an opioid OD treated in two urban emergency departments (ED) during an ongoing fentanyl OD epidemic were reviewed. Definitions for OW and opioid reversal were developed a priori. Low dose naloxone (LDN; ≤0.15 mg) and high dose naloxone (HDN; >0.15 mg) patients were matched in a 1:4 ratio based upon initial respiratory rate (RR). The proportion of patients who developed OW and who met reversal criteria were compared between those treated initially with LDN or HDN. Odds ratios (OR) for OW and opioid reversal were obtained via logistic regression stratified by matched sets and adjusted for age, sex, pre-naloxone GCS, and presence of non-opioid drugs or alcohol.
RESULTS: Eighty LDN patients were matched with 299 HDN patients. After adjustment, HDN patients were more likely than LDN patients to have OW after initial dose (OR = 8.43; 95%CI: 1.96, 36.3; p = 0.004) and after any dose (OR = 2.56; 95%CI: 1.17, 5.60; p = 0.019). HDN patients were more likely to meet reversal criteria after initial dose (OR = 2.73; 95%CI: 1.19, 6.26; p = 0.018) and after any dose (OR = 6.07; 95%CI: 1.81, 20.3; p = 0.003).
CONCLUSIONS: HDN patients were more likely to have OW but also more likely to meet reversal criteria versus LDN patients.
参考来源
- Purssell R, Godwin J, Moe J, et al. Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study. Clin Toxicol (Phila). 2020. PMID: 32401548. doi:10.1080/15563650.2020.1758325
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。